Compare WVE & FIHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WVE | FIHL |
|---|---|---|
| Founded | 2012 | 2014 |
| Country | Singapore | Bermuda |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.0B |
| IPO Year | 2015 | 2015 |
| Metric | WVE | FIHL |
|---|---|---|
| Price | $7.26 | $19.09 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 16 | 7 |
| Target Price | ★ $30.25 | $22.50 |
| AVG Volume (30 Days) | ★ 5.4M | 374.1K |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | N/A | ★ 3.16% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,704,000.00 | N/A |
| Revenue This Year | $0.34 | $16.34 |
| Revenue Next Year | $83.30 | $7.05 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 149.43 | N/A |
| 52 Week Low | $5.02 | $14.67 |
| 52 Week High | $21.73 | $20.50 |
| Indicator | WVE | FIHL |
|---|---|---|
| Relative Strength Index (RSI) | 30.10 | 50.49 |
| Support Level | $6.94 | $17.93 |
| Resistance Level | $8.29 | $19.25 |
| Average True Range (ATR) | 0.75 | 0.34 |
| MACD | -0.50 | 0.03 |
| Stochastic Oscillator | 26.85 | 60.75 |
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
Fidelis Insurance Holdings Ltd is a specialty insurer that leverages strategic partnerships to offer tailored insurance solutions. The company classifies its business into two segments, Insurance and Reinsurance. A majority of its revenue is generated from the Insurance segment, which comprises a portfolio of property, marine, aviation and aerospace, political risk, violence and terror, energy, cyber, and other insurance risks. The Reinsurance segment consists of an actively managed property reinsurance book, providing reinsurance and a limited amount of retrocession coverage across the world on a proportional or excess-of-loss basis. Geographically, the company derives its key revenue from the United Kingdom, followed by Bermuda and the Republic of Ireland.